8 completed, 3 terminated, 3 withdrawn, 1 active not recruiting. 10 Phase 2, 4 Not applicable, 4 Phase 1, 1 Early Phase 1.
Follow Hematopoietic Cell Transplantation Recipient: new trials by email Literature Review of Hematopoietic Cell Transplantation Recipient trials Research Report on Hematopoietic Cell Transplantation Recipient
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of an Online ACT Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation Acceptance and Commitment Therapy, Education - Hematopoietic Cell Transplantation Recipient, Acceptance and Commitment Therapy | Not applicable | Unknown | University of Social Sciences and Humanities, Warsaw | 192 | 2024-03-06 | 2024-05-16 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide - Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient | Phase 1 | Withdrawn | City of Hope Medical Center | 2018-12-30 | 2018-12-07 | |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-12-01 | 2018-11-21 | |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study - Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma | Phase 2 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2018-09-01 | 2020-02-21 | |
| SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart Monitoring Device, Informational Intervention, Questionnaire Administration - Acute Leukemia in Remission, Hematopoietic Cell Transplantation Recipient | Not applicable | Completed | Fred Hutchinson Cancer Center | 41 | 2018-08-31 | 2024-01-23 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome Fludarabine, Laboratory Biomarker Analysis, Melphalan - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission | Phase 1 | Suspended | City of Hope Medical Center | 36 | 2018-07-06 | 2026-09-28 |
| Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers Booklet, Exercise Intervention, Quality-of-Life Assessment - Hematopoietic Cell Transplantation Recipient | Not applicable | Completed | Fred Hutchinson Cancer Center | 29 | 2018-05-18 | 2020-03-04 |
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Ibrutinib, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Andrew Rezvani | 8 | 2017-09-12 | 2023-08-01 |
| Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant Dietary Intervention, Laboratory Biomarker Analysis - Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient | Not applicable | Terminated | Rutgers, The State University of New Jersey | 7 | 2017-08-22 | 2021-08-23 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2017-06-09 | 2019-10-21 |
| High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis - Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 170 | 2016-09-01 | 2024-10-22 |
| Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Elotuzumab, Lenalidomide, Questionnaire Administration - Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 113 | 2015-04-14 | 2026-10-06 |
| Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant Eltrombopag Olamine, Laboratory Biomarker Analysis - Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2013-10-14 | 2024-04-23 |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Ixazomib Citrate, Lenalidomide, Questionnaire Administration - Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma | Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2012-12-03 | 2025-01-28 |
| Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2012-10-25 | 2025-02-28 |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Assessment of Therapy Complications, Questionnaire Administration - Hematopoietic Cell Transplantation Recipient, Leukemia | Recruiting | Children's Oncology Group | 25000 | 2008-07-17 | 2026-10-20 | |
| Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders Bone Marrow Transplantation, CliniMACS CD34 Reagent System, Peripheral Blood Stem Cell Transplantation - Benign Neoplasm, Bone Marrow Transplantation Recipient | Available | OHSU Knight Cancer Institute | 2026-07-27 |
Multiple Myeloma (4) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia, Myeloid, Acute (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (3) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Neoplasm, Residual (2) · Neoplasms (2)
Hemic and Lymphatic Diseases (13) · Neoplasms (13) · Immune System Diseases (12) · Neoplasms by Histologic Type (12) · Immunoproliferative Disorders (11) · Lymphoproliferative Disorders (11) · Hematologic Diseases (9) · Lymphatic Diseases (8) · Bone Marrow Diseases (5) · Cardiovascular Diseases (5) · Leukemia (5) · Leukemia, Lymphoid (5) · Lymphoma (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Melphalan (3) · Etoposide (2) · Lenalidomide (2) · Peripheral Blood Stem Cell Transplantation (2) · Tacrolimus (2) · Acceptance and Commitment Therapy (1) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Busulfan (1) · CT-P10 (1) · Carmustine (1) · Clofarabine (1) · Cyclophosphamide (1) · Cytarabine (1) · Diet Therapy (1)
M.D. Anderson Cancer Center (4) · City of Hope Medical Center (3) · Fred Hutchinson Cancer Center (3) · Ohio State University Comprehensive Cancer Center (2) · Rutgers, The State University of New Jersey (2) · Andrew Rezvani (1) · Children's Oncology Group (1) · OHSU Knight Cancer Institute (1) · University of Social Sciences and Humanities, Warsaw (1) · Vanderbilt-Ingram Cancer Center (1)
United States (18) · Poland (1) · Puerto Rico (1)
Roger Strair (2) · Aleksandra Kroemeke, PhD (1) · Andrew Rezvani (1) · Ashley Rosko, MD (1) · David Garcia (1) · Eneida Nemecek, MD (1) · Eric Chow (1) · Kami Maddocks, MD (1) · Karamjeet Sandhu (1) · Krina Patel (1) · Monzr Al Malki (1) · Natasha Halasa, MD, MPH (1) · Ryotaro Nakamura, MD (1) · Sheeba Thomas (1) · Smita Bhatia (1)
PMID 33037989, PMID 37800415, PMID 38890709, PMID 39279435
P30CA015704 (3), P30CA072720 (2), P30CA016058 (1), U10CA098543 (1), U10CA180886 (1), UG1CA189955 (1), UG1CA189958 (1)